🚀 VC round data is live in beta, check it out!
bioXXmed Valuation Multiples
Discover revenue and EBITDA valuation multiples for bioXXmed and similar public comparables like Lipigon Pharmaceuticals, Lidds, DanCann Pharma, Oxurion and more.
bioXXmed Overview
About bioXXmed
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
Founded
2000
HQ
Employees
1
Website
Sectors
Financials (FY)
EV
$337K
bioXXmed Stock Performance
bioXXmed has current market cap of $270K, and enterprise value of $337K.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $337K | $270K | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialbioXXmed Valuation Multiples
bioXXmed Financial Valuation Multiples
As of March 11, 2026, bioXXmed has market cap of $270K and EV of $337K.
Equity research analysts estimate bioXXmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $270K | XXX | $270K | XXX | XXX | XXX |
| EV (current) | $337K | XXX | $337K | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified bioXXmed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
bioXXmed Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lipigon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Lidds | XXX | XXX | XXX | XXX | XXX | XXX |
| DanCann Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxurion | XXX | XXX | XXX | XXX | XXX | XXX |
| Itoco | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
bioXXmed M&A Activity
bioXXmed acquired XXX companies to date.
Last acquisition by bioXXmed was on XXXXXXXX, XXXXX. bioXXmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by bioXXmed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialbioXXmed Investment Activity
bioXXmed invested in XXX companies to date.
bioXXmed made its latest investment on XXXXXXXX, XXXXX. bioXXmed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by bioXXmed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout bioXXmed
| When was bioXXmed founded? | bioXXmed was founded in 2000. |
| Where is bioXXmed headquartered? | bioXXmed is headquartered in Germany. |
| How many employees does bioXXmed have? | As of today, bioXXmed has over 1 employees. |
| Is bioXXmed publicly listed? | Yes, bioXXmed is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of bioXXmed? | bioXXmed trades under T5O0 ticker. |
| When did bioXXmed go public? | bioXXmed went public in 2007. |
| Who are competitors of bioXXmed? | bioXXmed main competitors are Lipigon Pharmaceuticals, Lidds, DanCann Pharma, Oxurion. |
| What is the current market cap of bioXXmed? | bioXXmed's current market cap is $270K. |
| Is bioXXmed profitable? | No, bioXXmed is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.